5-Azacitidine in Low-risk Myelodysplastic Syndromes (MDSs)
NCT00897130
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
28
Enrollment
OTHER
Sponsor class
Conditions
Myelodysplastic Syndrome
Interventions
DRUG:
Azacytidine
Sponsor
Università degli Studi di Brescia
Collaborators
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]